GlassScriptPhysician profile
Robert Walter Bucher
NPI 1023082021
$3,765.95
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $752 · 2021: $1,488 · 2022: $429 · 2023: $152 · 2024: $76.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,116.67 | 2019-2024 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Novo Nordisk INC | $413.50 | 2019-2024 | Wegovy |
| Amgen INC. | $385.68 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.35 | 2019-2022 | |
| Pfizer INC. | $171.02 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $157.70 | 2019-2022 | |
| Astellas Pharma US INC | $105.10 | 2019-2021 | |
| Therapeuticsmd, INC. | $102.38 | 2019-2022 | |
| Allergan, INC. | $100.82 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $83.43 | 2019 | |
| Organon LLC | $75.00 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $72.41 | 2019-2021 | |
| Exeltis, USA INC. | $71.71 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $69.00 | 2020-2022 | |
| Avion Pharmaceuticals | $68.45 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $57.22 | 2021 | |
| Mayne Pharma Commercial LLC | $56.63 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.29 | 2019-2020 | |
| Lupin INC. | $53.38 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $51.06 | 2021 | |
| Eisai INC. | $46.38 | 2019-2020 | |
| Axonics, INC. | $40.52 | 2020-2021 | |
| Duchesnay USA Incorporated | $40.40 | 2019 | |
| Sage Therapeutics, LLC | $34.73 | 2021 | |
| Mission Pharmacal Company | $30.88 | 2019-2020 | |
| Dysis Medical, INC. | $22.38 | 2019 | |
| Alydia Health | $21.44 | 2021 | |
| Millicent US INC | $18.30 | 2021 | |
| Myovant Sciences INC. | $16.52 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.02 | 2022 | |
| Hologic Sales and Service, LLC | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bucher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.